Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819282 | 1.00 | POLB (0.52) | POLBDNMT1CYP2D6HTR6DRD2 | |
| SCHEMBL374903 | 0.86 | GPR84 (0.40) | POLBDRD2DRD4ALDH1A1KMT2A | |
| SCHEMBL820876 | 0.86 | POLB (0.49) | POLBDNMT1CYP2D6HTR6KDM4E | |
| SCHEMBL818363 | 0.86 | POLB (0.49) | POLBDNMT1CYP2D6HTR6KDM4E | |
| SCHEMBL823068 | 0.84 | DRD4 (0.43) | POLBHTR6DRD2DRD4DRD3 | |
| SCHEMBL818209 | 0.84 | DRD4 (0.43) | POLBHTR6DRD2DRD4DRD3 | |
| SCHEMBL28789715 | 0.83 | DNMT1 (0.59) | DNMT1CYP2D6HTR6DRD2DRD4 | |
| SCHEMBL12303282 | 0.82 | HTR6 (0.60) | POLBDNMT1HTR6 | |
| SCHEMBL12167363 | 0.82 | HTR6 (0.60) | POLBDNMT1HTR6 | |
| SCHEMBL823090 | 0.81 | POLB (0.55) | POLBDNMT1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUITCAL CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2009094287-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICAL CORPORATION (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288116-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC7 | POLB 3282/4885DNMT1 3045/4885CYP2D6 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.